Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Pre-clinical research

ATR inhibitors induce cell death in ALT-positive osteosarcoma and glioblastoma cells

Human cancers use the alternative lengthening of telomeres (ALT) pathway in order to overcome cell death. This could be used as potential treatment for vulnerable tumours. In the image, human chromosome with telomeres (in pink).

Source: Science Photo Library

Around 5% of human cancers use telomerase and the alternative lengthening of telomeres (ALT) pathway to overcome the usual process of ageing and cell death

Around 5% of human cancers use telomerase and the alternative lengthening of telomeres (ALT) pathway in order to overcome the usual process of ageing and cell death. This survival mechanism is being targeted as a potential treatment for vulnerable tumours.

Writing in Science (2015;347:273–277)[1], researchers led by Rachel Litman Flynn, from Harvard Medical School, reveal that the chromatin remodelling protein ATRX plays a critical role in regulating the ALT pathway. They also showed that inhibiting the protein kinase ATR induced cell death in vitro in ALT-positive osteosarcoma and glioblastoma cells.

This effect was highly selective for cancers that rely on ALT for survival, suggesting that ATR inhibition may be a useful treatment approach in ALT-positive cancers.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20067622

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.